Sustained virologic response to treatment in 100% of patients recently infected, nosocomially, with HCV genotype 2

Journal of Clinical Gastroenterology

Volumn 42, Issue 6, 2008, Pages 730-733

  Sikuler, Emanuel ^a,d   Tur Kaspa, Ran ^b   Shemer Avni, Yonat ^a   Delgado, Jorge ^a   Zilberman, Doron ^a   Fich, Alexander ^a   Baruch, Yaacov ^c   Hyam, Eytan ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Genotype 2; Hepatitis C; Interferon; Nosocomial infection; Ribavirin; SVR

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS 2; HOSPITAL INFECTION; HUMAN; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RNA ISOLATION; RNA SEQUENCE; SEQUENCE HOMOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIROLOGY; ADOLESCENT; CROSS INFECTION; DRUG EFFECT; FOLLOW UP; GENETICS; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; TIME;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; COHORT STUDIES; CROSS INFECTION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PHOSPHORYLATION; RNA, VIRAL; SEQUENCE HOMOLOGY, NUCLEIC ACID; TIME FACTORS; TREATMENT OUTCOME;

EID: 54749154118     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31804c7053     Document Type: Article

References (15)

1. Forns X, Bruguera M. Nosocomial transmission of HCV. Hepatol Rev. 2004;1:52-58.
2. Shemer-Avni Y, Cohen M, Naos A, et al. Comparative molecular analysis of HRV1 and HRV2 to detect transmission of HCV genotype 2 from an anesthesiologist to 32 patients. Hepatology. 2005;42(suppl 1):212A.
3. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
4. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotype 2 or 3. J Hepatol. 2004;40:993-999.
5. Taylor DR, Shi ST, Romano PR, et al. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science. 1999; 285:107-110.
6. Saito T, Ito T, Ishiko H, et al. PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotype 2a and 2b. Am J Gastroenterol. 2003;98:1377-1383.
7. Strader DB, Wright T, Thomas DL, et al. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-1171.
8. Persico M, Perrotta S, Persico E et al. Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. J Viral hepatol. 2006;13:290-296.
9. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958-965.
10. Martinez-Bauer E, Crespo J, Romero-Gomez M, et al. Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. Hepatology. 2006;43:72-80.
11. Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology. 2004;40:1260-1265.
12. McHutchison JG, Manns M, Patel K, et al. International interventional therapy group. Adherence to combination therapy enhances response in genotype 1 infected patients with chronic hepatitis C. Gastroenterology. 2003;125:1284-1286.
13. Manns MP. Adherence to combination therapy: influence on sustained virological response and economic impact. Gastrenterol Clin North Am. 2004;33:S11-S24.
14. von Wagner M, Huber M, Berg T, et al. Peginterferonalpha-2a (40 KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroeneterology. 2005;129: 522-527.
15. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.